Mark X. Sliwkowski

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.6K citations

Drug Targeting, Breast Oncology, Disulfide Linkers +12

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

Jennifer L. Stamos, Mark X. Sliwkowski, Charles Eigenbrot · Journal of Biological Chemistry · 2002 · 1.5K citations · Full text

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Jagath R. Junutula, Helga Raab, Suzanna Clark et al. · Nature Biotechnology · 2008 · 1.3K citations

Medicinal Chemistry, Immunocytochemical Technique, Drug Targeting +10

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Matthew C. Franklin, Kendall D. Carey, F.F. Vajdos et al. · Cancer Cell · 2004 · 1.1K citations · Full text

Protein Function, Signal Transduction, Signaling Pathway +9

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

Ben‐Quan Shen, Keyang Xu, Luna Liu et al. · Nature Biotechnology · 2012 · 977 citations

Immunoengineering, Immunology, Bioconjugation +8